Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Orbit (Amsterdam, Netherlands)|August 19, 2017
Orbital mantle cell lymphoma presenting as myasthenia gravisJustin Karlin, Travis Peck, Karyn Prenshaw, et al.
Ophthalmology|October 23, 2013
Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomesMary E Aronow, Craig A Portell, John W Sweetenham, et al.
Clinical Case Reports|October 15, 2025
Relapsed Chronic Lymphocytic Leukemia Heralded by Parathyroid Hormone Related Peptide-Mediated HypercalcemiaSrikar Tallavajhala, Joanna Lee, Sean C Dougherty, et al.
Clinical Trials (London, England)|March 30, 2024
Applications of the partial-order continual reassessment method in the early development of treatment combinationsNolan A Wages, Patrick M Dillon, Craig A Portell, et al.
Ophthalmology|May 14, 2013
Ocular adnexal lymphoma: assessment of a tumor-node-metastasis staging systemMary E Aronow, Craig A Portell, Lisa A Rybicki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2017
Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted AgentsNolan A Wages, Craig A Portell, Michael E Williams, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 15, 2014
Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtypeCraig A Portell, Mary E Aronow, Lisa A Rybicki, et al.
British Journal of Haematology|July 30, 2013
The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathwaysJuraj Bodo, Xiaoxian Zhao, Arishya Sharma, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2018
Risk of Major Bleeding with IbrutinibJoseph Mock, Paul R Kunk, Surabhi Palkimas, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 28, 2026
An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404Jonathon B Cohen, Craig A Portell, Mehdi Hamadani, et al.
Pageof 5